Tracking SARS-CoV-2 evolution: notable mutations and potential targets
Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
List view / Grid view
Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
Scientists have developed a novel secretory immunoglobulin A (sIgA) serotype antibody that binds more effectively to the spike protein of SARS-CoV-2 than some IgG antibodies.
Scientists have revealed that the cytokines IL-6 and TNF-α are two biomarkers of inflammation that can predict the severity of COVID-19.
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
A compound called BOLD-100, which has shown efficacy against COVID-19 in pre-clinical trials, has now outperformed remdesivir in a cytopathic effect assay.
A potential COVID-19 vaccine, made from a modified vesicular stomatitis virus with the SARS-CoV-2 Spike protein, was shown to protect mice against the virus.
Researchers have found that the SARS-CoV-2 nucleocapsid protein may help the virus to spread from cell to cell, providing a drug target.
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
A team has developed a predictive tool called TransComp-R which could be used to reveal whether new drugs that have been effective in animals will have positive outcomes in humans.
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
Researchers have sequenced SARS-CoV-2, revealing at least six strains with little variability, useful information for vaccine developers.
A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.